Six-year contraceptive efficacy and continued safety of a levonorgestrel 52 mg intrauterine system

Carolyn L. Westhoff; Lisa M. Keder; Angelina Gangestad; Stephanie B. Teal; Andrea I. Olariu; Mitchell D. Creinin

doi:10.1016/j.contraception.2019.10.010

Six-year contraceptive efficacy and continued safety of a levonorgestrel 52 mg intrauterine system

Carolyn L. Westhoff, Lisa M. Keder, Angelina Gangestad, Stephanie B. Teal, Andrea I. Olariu, Mitchell D. Creinin

Obstetrics and Gynecology

Research output: Contribution to journal › Article

Abstract

Objective: To assess 6-year contraceptive efficacy and safety of a levonorgestrel 52 mg intrauterine system (IUS). Study Design: We assessed pregnancy rates through 72 months in women aged 16–35 years at enrollment and safety in all participants (aged 16–45 years, n = 1751) in an ongoing 10-year phase-3 trial. Results: Over six years, nine pregnancies occurred (none in year 6) for a life-table pregnancy rate of 0.87 (95% CI 0.44–1.70). Adverse event rates remain low through 6 or more years of use. Two expulsions occurred in year 6. Conclusion: This levonorgestrel 52 mg IUS is a highly effective and safe contraceptive over 6 years of use. Implications: The levonorgestrel 52 mg IUS shows high 6-year contraceptive efficacy and a low rate of adverse events through 6 or more years of use.

Original language	English (US)
Journal	Contraception
DOIs	https://doi.org/10.1016/j.contraception.2019.10.010
State	Accepted/In press - Jan 1 2019

Keywords

Efficacy
Intrauterine system
Levonorgestrel
Liletta
Safety

ASJC Scopus subject areas

Reproductive Medicine
Obstetrics and Gynecology

Access to Document

10.1016/j.contraception.2019.10.010

Fingerprint Dive into the research topics of 'Six-year contraceptive efficacy and continued safety of a levonorgestrel 52 mg intrauterine system'. Together they form a unique fingerprint.

Cite this

Westhoff, C. L., Keder, L. M., Gangestad, A., Teal, S. B., Olariu, A. I., & Creinin, M. D. (Accepted/In press). Six-year contraceptive efficacy and continued safety of a levonorgestrel 52 mg intrauterine system. Contraception. https://doi.org/10.1016/j.contraception.2019.10.010

@article{34f9e2df4a2f44c89e5ae35c7b26942c,

title = "Six-year contraceptive efficacy and continued safety of a levonorgestrel 52 mg intrauterine system",

abstract = "Objective: To assess 6-year contraceptive efficacy and safety of a levonorgestrel 52 mg intrauterine system (IUS). Study Design: We assessed pregnancy rates through 72 months in women aged 16–35 years at enrollment and safety in all participants (aged 16–45 years, n = 1751) in an ongoing 10-year phase-3 trial. Results: Over six years, nine pregnancies occurred (none in year 6) for a life-table pregnancy rate of 0.87 (95% CI 0.44–1.70). Adverse event rates remain low through 6 or more years of use. Two expulsions occurred in year 6. Conclusion: This levonorgestrel 52 mg IUS is a highly effective and safe contraceptive over 6 years of use. Implications: The levonorgestrel 52 mg IUS shows high 6-year contraceptive efficacy and a low rate of adverse events through 6 or more years of use.",

keywords = "Efficacy, Intrauterine system, Levonorgestrel, Liletta, Safety",

author = "Westhoff, {Carolyn L.} and Keder, {Lisa M.} and Angelina Gangestad and Teal, {Stephanie B.} and Olariu, {Andrea I.} and Creinin, {Mitchell D.}",

year = "2019",

month = jan,

day = "1",

doi = "10.1016/j.contraception.2019.10.010",

language = "English (US)",

journal = "Contraception",

issn = "0010-7824",

publisher = "Elsevier USA",

}

TY - JOUR

T1 - Six-year contraceptive efficacy and continued safety of a levonorgestrel 52 mg intrauterine system

AU - Westhoff, Carolyn L.

AU - Keder, Lisa M.

AU - Gangestad, Angelina

AU - Teal, Stephanie B.

AU - Olariu, Andrea I.

AU - Creinin, Mitchell D.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objective: To assess 6-year contraceptive efficacy and safety of a levonorgestrel 52 mg intrauterine system (IUS). Study Design: We assessed pregnancy rates through 72 months in women aged 16–35 years at enrollment and safety in all participants (aged 16–45 years, n = 1751) in an ongoing 10-year phase-3 trial. Results: Over six years, nine pregnancies occurred (none in year 6) for a life-table pregnancy rate of 0.87 (95% CI 0.44–1.70). Adverse event rates remain low through 6 or more years of use. Two expulsions occurred in year 6. Conclusion: This levonorgestrel 52 mg IUS is a highly effective and safe contraceptive over 6 years of use. Implications: The levonorgestrel 52 mg IUS shows high 6-year contraceptive efficacy and a low rate of adverse events through 6 or more years of use.

AB - Objective: To assess 6-year contraceptive efficacy and safety of a levonorgestrel 52 mg intrauterine system (IUS). Study Design: We assessed pregnancy rates through 72 months in women aged 16–35 years at enrollment and safety in all participants (aged 16–45 years, n = 1751) in an ongoing 10-year phase-3 trial. Results: Over six years, nine pregnancies occurred (none in year 6) for a life-table pregnancy rate of 0.87 (95% CI 0.44–1.70). Adverse event rates remain low through 6 or more years of use. Two expulsions occurred in year 6. Conclusion: This levonorgestrel 52 mg IUS is a highly effective and safe contraceptive over 6 years of use. Implications: The levonorgestrel 52 mg IUS shows high 6-year contraceptive efficacy and a low rate of adverse events through 6 or more years of use.

KW - Efficacy

KW - Intrauterine system

KW - Levonorgestrel

KW - Liletta

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=85076574430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076574430&partnerID=8YFLogxK

U2 - 10.1016/j.contraception.2019.10.010

DO - 10.1016/j.contraception.2019.10.010

M3 - Article

C2 - 31786203

AN - SCOPUS:85076574430

JO - Contraception

JF - Contraception

SN - 0010-7824

ER -

Six-year contraceptive efficacy and continued safety of a levonorgestrel 52 mg intrauterine system

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Cite this

Six-year contraceptive efficacy and continued safety of a levonorgestrel 52 mg intrauterine system